Phase II trial of (m-AMSA) 4′-9-(acridinylamino)-metlianesulfon-m-aniside in primary liver cancer

Publisher Website
Google Scholar
Abstract
Between february 1979 and July 1980, 16 patients with hepatocellular carcinoma and one patient with hepatoblastoma were entered into a phase II trial of m-AMSA at Memorial Hospital. m-AMSA was administered intravenously every 21–28 days in doses ranging from 90 mg/m2-170 mg/m2. Toxicities included leukopenia (14 patients), thrombocytopenia (2 patients), alopecia (1 patient), mucositis (1 patient), and mild to moderate nausea and vomiting (2 patients). No responses were seen in any patients.